TABLE 2

Study Details

StudyDuration IV in Days (Range)Total Duration of Therapy in Days (Range)Antibiotics UsedS aureus–Positive Culture: % of All Isolates (Reported MSSA vs MRSA)Percent With Complication
Peltola3.9a (0–14)20: 67 patients; 30: 64 patients (10–43)Clindamycin, first-generation cephalosporin89 (all MSSA)1.5 (2 patients)
Jagodzinki3.75b (2–15)21 d after IV (28 patients); extended (9 patients)cPenicillinase-resistant penicillin100d0
Zaoutis<10 vs >10NAFirst-generation cephalosporin, penicillinase-resistant penicillin clindamycinMSSA average 32.5; MRSA average 7.5e4.7 vs 5f
Bachur4b (0–7)32 (20-49)First-generation cephalosporin85 (all MSSA)0
Jaberi10 or 2128 d after IVCephalosporin with aminoglycoside100d0
Vinod3b38g (20–46)First-generation cephalosporin, penicillinase-resistant penicillin65d0
  • d, days; MRSA, methicillin-resistant S aureus.

  • a Average of 2 study groups.

  • b Median.

  • c Specifics not reported.

  • d Authors did not report MSSA versus MRSA.

  • e Average of short and long IV groups combined.

  • f Short- versus long-course IV.

  • g Converted from weeks.